Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.

Autor: Olalla, Julián, Pérez-Stachowski, Javier, Tortajada, Begoña, Arco, Alfonso Del, Márquez, Efrén, De la Torre, Javier, Nieto, Miriam, de Lomas, José María García, Prada, José Luis, García-Alegría, Javier
Předmět:
Zdroj: BMC Pharmacology & Toxicology; 10/6/2023, Vol. 24 Issue 1, p1-1, 1p
Abstrakt: B Correction to: b B I BMC Pharmacol Toxicol i b B 19, 63 (2018). b https://doi.org/10.1186/s40360-018-0252-z The original publication of this article did not provide clear clarification that the switch from brand to a generic drug was not done by the authors for the intention of the study. Patients were informed of the options and on switching to generic drugs the patients were able to expressed their agreements or disagreements, those who expressed their disagreement continued with their regimen. Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz: